NK Cell Gene Delivery via RIG-I Suppression With 7-Oxozeaenol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods face challenges in efficiently delivering genetic materials to natural killer cells, hematopoietic stem cells, and macrophages due to their inherent resistance to retroviral infections and activation of intracellular defense mechanisms.
Innovation Solution
Co-administration of (5Z)-7-Oxozeaenol with a viral vector to downregulate intracellular defense mechanisms, specifically targeting RIG-I, enhances gene delivery and transfection efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used to deliver genetic materials to NK cells, macrophages, and stem cells, then gene delivery is attempted, but transfection efficiency is low due to inherent resistance to retroviral infections and activation of intracellular defense mechanisms
Solution Approach 1:
The patent uses (5Z)-7-Oxozeaenol as an intermediary substance that mediates between the viral vector and the target cells. This small molecule inhibitor acts as a bridge to suppress the intracellular defense mechanisms (RIG-I pathway) that normally block viral vector entry, thereby facilitating gene delivery without requiring modification of the viral vector or target cells
Solution Approach 2:
The patent changes the chemical parameter state of the intracellular environment by introducing (5Z)-7-Oxozeaenol, which alters the activity state of the RIG-I pathway. This parameter change (inhibiting RIG-I signaling) transforms the cellular state from resistant to permissive for viral vector entry, thereby improving transfection efficiency
2Object-affected harmful factors
If intracellular defense mechanisms are activated to protect against viral infection, then cell protection is improved, but gene delivery efficiency deteriorates
Solution Approach 1:
The patent converts the harmful effect of intracellular defense mechanisms into a benefit by using (5Z)-7-Oxozeaenol to selectively inhibit the RIG-I pathway during gene delivery. The same pathway that normally protects against viral infection is temporarily suppressed to enable therapeutic gene delivery, and this suppression is controlled to minimize off-target effects
Solution Approach 2:
The patent applies preliminary anti-action by pre-treating cells with (5Z)-7-Oxozeaenol before viral vector delivery. This preliminary inhibition of the RIG-I pathway prevents the activation of defense mechanisms that would otherwise block gene delivery, allowing efficient transfection to occur
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly improves gene delivery and transfection efficiency in NK cells, macrophages, and stem cells, with minimal toxicity and enhanced proliferation, enabling effective treatment of cancer, genetic disorders, and viral inflammation.
Implementation Method 1
downregulation of intracellular defense mechanisms mediated by Rig I
Data Source
AI summary
The present invention comprises a method of downregulating intracellular defenses by administering (5Z)-7-Oxozeaenol. This allows for improved delivery of RNA based gene vectors to natural killer, stem and macrophage cells. The resulting cells can be used in adoptive cell transfer therapies. Also provided are methods of treating virally induced inflammation via administration of (5Z)-7-Oxozeaenol together with an anti viral therapeutic.